Sec Form 13D Filing - ARCH Venture Fund IX L.P. filing for Vir Biotechnology Inc. (VIR) - 2022-09-13

  

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

  

 

SCHEDULE 13D

 

 

 

Under the Securities Exchange Act of 1934

(Amendment No. 6)*

 

 

Vir Biotechnology, Inc. 

(Name of Issuer)

 

 

Common Stock, $0.0001 par value

(Title of Class of Securities)

 

 

   92764N 102  

(CUSIP Number)

 

 

Mark McDonnell

ARCH Venture Management, LLC

8755 W. Higgins Road Suite 1025

      Chicago, IL 60631     

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

 

 

    August 12, 2022   

(Date of Event which Requires Filing of this Statement)

 

 

 

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐

 

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.

 

*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

 

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 

 

Persons who respond to the collection of information contained in this form are not
required to respond unless the form displays a currently valid OMB control number.

 

CUSIP No. 92764N 102

13D

Page 2 of 17 Pages

 

1		NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)   ARCH Venture Fund IX, L.P.
2		CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)		(a) ☐ (b) ☐
3		SEC USE ONLY
4		SOURCE OF FUNDS (see instructions)    WC
5		CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)		☐
6		CITIZENSHIP OR PLACE OF ORGANIZATION   Delaware

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		7		SOLE VOTING POWER   0 Shares
		8		SHARED VOTING POWER   12,916,663 shares
		9		SOLE DISPOSITIVE POWER   0 Shares
		10		SHARED DISPOSITIVE POWER   12,916,663 shares

11		AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON   12,916,663 shares
12		CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)		☐
13		PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)    9.7%
14		TYPE OF REPORTING PERSON (see instructions)     PN

 

CUSIP No. 92764N 102

13D

Page 3 of 17 Pages

 

1		NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)   ARCH Venture Fund IX Overage, L.P.
2		CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)		(a) ☐ (b) ☐
3		SEC USE ONLY
4		SOURCE OF FUNDS (see instructions)    WC
5		CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)		☐
6		CITIZENSHIP OR PLACE OF ORGANIZATION   Delaware

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		7		SOLE VOTING POWER   0 Shares
		8		SHARED VOTING POWER   12,916,663 shares
		9		SOLE DISPOSITIVE POWER   0 Shares
		10		SHARED DISPOSITIVE POWER   12,916,663 shares

11		AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON   12,916,663 shares
12		CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)		☐
13		PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)    9.7%
14		TYPE OF REPORTING PERSON (see instructions)     PN

 

CUSIP No. 92764N 102

13D

Page 4 of 17 Pages

 

1		NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)   ARCH Venture Partners IX, L.P.
2		CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)		(a) ☐ (b) ☐
3		SEC USE ONLY
4		SOURCE OF FUNDS (see instructions)    AF
5		CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)		☐
6		CITIZENSHIP OR PLACE OF ORGANIZATION   Delaware

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		7		SOLE VOTING POWER   0 Shares
		8		SHARED VOTING POWER   12,916,663 shares
		9		SOLE DISPOSITIVE POWER   0 Shares
		10		SHARED DISPOSITIVE POWER   12,916,663 shares

11		AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON   12,916,663 shares
12		CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)		☐
13		PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)    9.7%
14		TYPE OF REPORTING PERSON (see instructions)     PN

 

CUSIP No. 92764N 102

13D

Page 5 of 17 Pages

 

1		NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)   ARCH Venture Partners IX Overage, L.P.
2		CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)		(a) ☐ (b) ☐
3		SEC USE ONLY
4		SOURCE OF FUNDS (see instructions)    WC
5		CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)		☐
6		CITIZENSHIP OR PLACE OF ORGANIZATION   Delaware

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		7		SOLE VOTING POWER   0 Shares
		8		SHARED VOTING POWER   12,916,663 shares
		9		SOLE DISPOSITIVE POWER   0 Shares
		10		SHARED DISPOSITIVE POWER   12,916,663 shares

11		AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON   12,916,663 shares
12		CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)		☐
13		PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)    9.7%
14		TYPE OF REPORTING PERSON (see instructions)     PN

 

CUSIP No. 92764N 102

13D

Page 6 of 17 Pages

 

1		NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)   ARCH Venture Partners IX, LLC
2		CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)		(a) ☐ (b) ☐
3		SEC USE ONLY
4		SOURCE OF FUNDS (see instructions)    AF
5		CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)		☐
6		CITIZENSHIP OR PLACE OF ORGANIZATION   Delaware

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		7		SOLE VOTING POWER   0 Shares
		8		SHARED VOTING POWER   12,916,663 shares
		9		SOLE DISPOSITIVE POWER   0 Shares
		10		SHARED DISPOSITIVE POWER   12,916,663 shares

11		AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON   12,916,663 shares
12		CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)		☐
13		PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)    9.7%
14		TYPE OF REPORTING PERSON (see instructions)     OO

 

CUSIP No. 92764N 102

13D

Page 7 of 17 Pages

 

1		NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)   Robert Nelsen
2		CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)		(a) ☐ (b) ☐
3		SEC USE ONLY
4		SOURCE OF FUNDS (see instructions)    AF
5		CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)		☐
6		CITIZENSHIP OR PLACE OF ORGANIZATION   United States

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		7		SOLE VOTING POWER   601,754 Shares
		8		SHARED VOTING POWER   12,950,556 shares
		9		SOLE DISPOSITIVE POWER   601,754 Shares
		10		SHARED DISPOSITIVE POWER   12,950,556 shares

11		AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON   13,552,310 shares
12		CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)		☐
13		PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)    10.2%
14		TYPE OF REPORTING PERSON (see instructions)     IN

 

CUSIP No. 92764N 102

13D

Page 8 of 17 Pages

 

1		NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)   Keith Crandell
2		CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)		(a) ☐ (b) ☐
3		SEC USE ONLY
4		SOURCE OF FUNDS (see instructions)    AF
5		CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)		☐
6		CITIZENSHIP OR PLACE OF ORGANIZATION   United States

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		7		SOLE VOTING POWER   272,964 Shares
		8		SHARED VOTING POWER   12,916,663 shares
		9		SOLE DISPOSITIVE POWER   272,964 Shares
		10		SHARED DISPOSITIVE POWER   12,916,663 shares

11		AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON   13,189,627 shares
12		CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)		☐
13		PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)    9.9%
14		TYPE OF REPORTING PERSON (see instructions)     IN

 

CUSIP No. 92764N 102

13D

Page 9 of 17 Pages

 

1		NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)   Clinton Bybee
2		CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)		(a) ☐ (b) ☐
3		SEC USE ONLY
4		SOURCE OF FUNDS (see instructions)    AF
5		CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)		☐
6		CITIZENSHIP OR PLACE OF ORGANIZATION   United States

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		7		SOLE VOTING POWER   30,570 Shares
		8		SHARED VOTING POWER   12,977,823 shares
		9		SOLE DISPOSITIVE POWER   30,570 Shares
		10		SHARED DISPOSITIVE POWER   12,977,823 shares

11		AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON   13,008,393 shares
12		CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)		☐
13		PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)    9.8%
14		TYPE OF REPORTING PERSON (see instructions)     IN

 

CUSIP No. 92764N 102

13D

Page 10 of 17 Pages

 

 

 

Schedule 13D

 

Item 1.

Security and Issuer.

 

This Amendment No. 6 (the “Amendment No.6”) to the statement filed on Schedule 13D filed on November 8, 2019 (the “Original 13D”), as amended by Amendment No. 5 (the “Amendment No. 5”) to the Original 13D filed on May 10, 2022, as amended by Amendment No. 4 (the “Amendment No. 4”) to the Original 13D filed on January 10, 2022, as amended by Amendment No. 3 (the “Amendment No. 3”) to the Original 13D filed on July 12, 2021, as amended by Amendment No. 2 (the “Amendment No. 2”) to the Original 13D filed on April 14, 2021, as amended by Amendment No. 1 (the “Amendment No. 1”) to the Original 13D filed on July 29, 2020, relating to the Common Stock, $0.0001 par value per share (the “Common Stock”), of Vir Biotechnology, Inc. (the “Issuer”) having its principal executive office at 499 Illinois Street, San Francisco, CA 94158.

 

Certain terms used but not defined in this Amendment No. 6 have the meanings assigned thereto in the Original 13D, Amendment No. 1, Amendment No. 2, Amendment No. 3, Amendment No. 4 and Amendment No. 5, as applicable. Except as specifically provided herein, this Amendment No. 6 does not modify any of the information previously reported on the Original 13D, Amendment No. 1, Amendment No. 2, Amendment No. 3, Amendment No. 4 or Amendment No. 5.

 

 

Item 4.

Purpose of Transaction.

 

Each of AVF IX and AVF IX Overage acquired the Common Stock for investment purposes.  Depending on market conditions, the continuing evaluation of the business and prospects of the Issuer and other factors, AVF IX and AVF IX Overage and other Reporting Persons may dispose of or acquire additional shares of Common Stock of the Issuer. 

 

On June 2, 2022, AVF IX and AVF IX Overage each made an in-kind distribution of 217,781 shares and 282,219 shares respectively, of Common Stock to its partners. As partners of AVP IX LP and AVP IX Overage GP each of Nelsen, Crandell and Bybee (and related family trusts) received shares in such distribution without payment of any consideration.

 

On June 8, 2022, AVF IX and AVF IX Overage each made an in-kind distribution of 217,781 shares and 282,219 shares respectively, of Common Stock to its partners. As partners of AVP IX LP and AVP IX Overage GP each of Nelsen, Crandell and Bybee (and related family trusts) received shares in such distribution without payment of any consideration.

 

On August 12, 2022, AVF IX and AVF IX Overage each made an in-kind distribution of 217,781 shares and 282,219 shares respectively, of Common Stock to its partners. As partners of AVP IX LP and AVP IX Overage GP each of Nelsen, Crandell and Bybee (and related family trusts) received shares in such distribution without payment of any consideration.

 

On August 15, 2022, AVF IX and AVF IX Overage each made an in-kind distribution of 217,781 shares and 282,219 shares respectively, of Common Stock to its partners. As partners of AVP IX LP and AVP IX Overage GP each of Nelsen, Crandell and Bybee (and related family trusts) received shares in such distribution without payment of any consideration.

 

On August 16, 2022, AVF IX and AVF IX Overage each made an in-kind distribution of 217,781 shares and 282,219 shares respectively, of Common Stock to its partners. As partners of AVP IX LP and AVP IX Overage GP each of Nelsen, Crandell and Bybee (and related family trusts) received shares in such distribution without payment of any consideration.

 

On August 18, 2022, AVF IX and AVF IX Overage each made an in-kind distribution of 217,781 shares and 282,219 shares respectively, of Common Stock to its partners. As partners of AVP IX LP and AVP IX Overage GP each of Nelsen, Crandell and Bybee (and related family trusts) received shares in such distribution without payment of any consideration.

 

 

 

CUSIP No. 92764N 102

13D

Page 11 of 17 Pages

 

 

On August 24, 2022, AVF IX and AVF IX Overage each made an in-kind distribution of 217,781 shares and 282,219 shares respectively, of Common Stock to its partners. As partners of AVP IX LP and AVP IX Overage GP each of Nelsen, Crandell and Bybee (and related family trusts) received shares in such distribution without payment of any consideration.

 

On August 25, 2022, AVF IX and AVF IX Overage each made an in-kind distribution of 217,781 shares and 282,219 shares respectively, of Common Stock to its partners. As partners of AVP IX LP and AVP IX Overage GP each of Nelsen, Crandell and Bybee (and related family trusts) received shares in such distribution without payment of any consideration.

 

On August 30, 2022, AVF IX and AVF IX Overage each made an in-kind distribution of 217,781 shares and 282,219 shares respectively, of Common Stock to its partners. As partners of AVP IX LP and AVP IX Overage GP each of Nelsen, Crandell and Bybee (and related family trusts) received shares in such distribution without payment of any consideration.

 

On August 31, 2022, AVF IX and AVF IX Overage each made an in-kind distribution of 217,781 shares and 282,219 shares respectively, of Common Stock to its partners. As partners of AVP IX LP and AVP IX Overage GP each of Nelsen, Crandell and Bybee (and related family trusts) received shares in such distribution without payment of any consideration.

 

On September 2, 2022, AVF IX and AVF IX Overage each made an in-kind distribution of 196,003 shares and 253,997 shares respectively, of Common Stock to its partners. As partners of AVP IX LP and AVP IX Overage GP each of Nelsen, Crandell and Bybee (and related family trusts) received shares in such distribution without payment of any consideration.

 

On September 6, 2022, AVF IX and AVF IX Overage each made an in-kind distribution of 239,559 shares and 310,441 shares respectively, of Common Stock to its partners. As partners of AVP IX LP and AVP IX Overage GP each of Nelsen, Crandell and Bybee (and related family trusts) received shares in such distribution without payment of any consideration.

 

Except as set forth above, none of the Reporting Persons has any present plans which relate to or would result in:

 

(a)

The acquisition by any person of additional securities of the Issuer, or the disposition of securities of the Issuer;

 

(b)

An extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving the Issuer or any of its subsidiaries;

 

(c)

A sale or transfer of a material amount of assets of the Issuer or any of its subsidiaries;

 

(d)

Any change in the present board of directors or management of the Issuer, including any plans or proposals to change the number or term of directors or to fill any existing vacancies on the board;

 

(e)

Any material change in the present capitalization or dividend policy of the Issuer;

 

(f)

Any other material change in the Issuer's business or corporate structure;

 

 

 

 

 

CUSIP No. 92764N 102

13D

Page 12 of 17 Pages

 

 

 

(g)

Changes in the Issuer's charter, bylaws or instruments corresponding thereto or other actions which may impede the acquisition of control of the Issuer by any person;

 

(h)

Causing a class of securities of the Issuer to be delisted from a national securities exchange or to cease to be authorized to be quoted in an inter-dealer quotation system of a registered national securities association;

 

(i)

A class of equity securities of the Issuer becoming eligible for termination of registration pursuant to Section 12(g)(4) of the Securities Exchange Act of 1934; or

 

(j)

Any action similar to any of those enumerated above.

 

 

Item 5.

Interest in Securities of the Issuer.

  

(a)

AVF IX is the record owner of 5,626,008 shares of Common Stock (“AVF IX Record Shares”). AVP IX LP, as the sole general partner of ARCH Venture Fund IX, may be deemed to beneficially own the AVF IX Record Shares.  AVP IX LLC, as the sole general partner of AVP IX LP, may be deemed to beneficially own the AVF IX Record Shares.

 

(b)

AVF IX Overage is the record holder of 7,290,655 shares of Common Stock (“IX Overage Record Shares” and, together with the AVF IX Record Shares, the “Record Shares”).  AVP IX Overage GP, as the sole general partner of ARCH IX Overage, may be deemed to beneficially own the IX Overage Record Shares.  AVP IX LLC, as the sole general partner of AVF IX Overage GP, may be deemed to beneficially own the IX Overage Record Shares.

 

By virtue of their relationship as affiliated entities who have overlapping general partners and managing directors, each entity and Reporting Person may be deemed to share the power to direct the disposition and vote of the Record Shares.  In addition, each of the AVP IX Managing Directors may be deemed to share the power to direct the disposition and vote of the Record Shares. Each Reporting Person disclaims beneficial ownership of all securities except for the shares, if any, held of record by such Reporting Person. Nelsen is also the holder of a vested option for 31,633 shares of Common Stock (the “Nelsen Options”). 

 

The percentage of outstanding Common Stock of the Issuer which may be deemed to be beneficially owned by each Reporting Person is set forth on Line 13 of such Reporting Person’s cover sheet.  Such percentage was calculated based on the 132,637,878 shares of Common Stock reported by the Issuer to be outstanding as of August 1, 2022 in the Issuer’s quarterly report on Form 10Q filed with the Securities and Exchange Commission on August 9, 2022. In addition, as of September 9, 2022, Crandell is a record holder of 272,964 Shares of Common Stock, Bybee is a record holder of 30,570 shares of Common Stock, and Nelsen is a beneficial owner of 601,754 shares of Common Stock including the Nelsen Options.  For Nelsen and Bybee, respectively, 33,893 shares and 61,160 share of Common Stock held by family trusts are included in Shared Voting and Shared Dispositive figures on cover sheets. For purposes of the percentage calculation for Nelsen, the Nelsen Options are included in the number of shares of Common Stock outstanding.

 

(b)

Regarding the number of shares as to which such person has:

 

(i)

sole power to vote or to direct the vote: See line 7 of cover sheets.

 

(ii)

shared power to vote or to direct the vote: See line 8 of cover sheets.

 

(iii)

sole power to dispose or to direct the disposition: See line 9 of cover sheets.

 

(iv)

shared power to dispose or to direct the disposition: See line 10 of cover sheets.

 

 

 

 

 

CUSIP No. 92764N 102

13D

Page 13 of 17 Pages

 

 

 

(c)

Except as set forth above, none of the Reporting Persons has effected any transaction in the Common Stock during the last 60 days.

 

(e)

No other person is known to have the right to receive or the power to direct the receipt of dividends from, or any proceeds from the sale of, shares beneficially owned by any of the Reporting Persons.

 

(f)

Not applicable.

 

 

 

Item 6.

Contracts, Arrangements, Undertakings or Relationships with Respect to Securities of the Issuer.

 

AVF IX and AVF IX Overage are parties to that certain Amended and Restated Investors’ Rights Agreement, dated November 29, 2017 (the “Investor Rights Agreement”), which is attached as an exhibit to the Issuer’s Form S-1 filed on September 30, 2019 and incorpo rated by reference herein. Effective as of the closing of the Issuer’s initial public offering, the covenants relating to delivery of financial statements, inspection rights and observer rights set forth in Section 3 were terminated. Pursuant to the Investor Rights Agreement, AVF IX and AVF IX Overage have certain registration rights with respect to its Common Stock.

 

 

 

Item 7.

Material to be Filed as Exhibits.

 

Exhibit 1 – Agreement of Joint Filing

 

Exhibit 2 – Investor Rights Agreement hereby incorporated by reference to the Issuer’s S-1 filed on September 30, 2019

 

 

 

 

 

 

 

 

 

 

CUSIP No. 92764N 102

13D

Page 14 of 17 Pages

 

 

 

Signature

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

Date:    September 13, 2022

 

ARCH VENTURE FUND IX, L.P.

 

By:       ARCH Venture Partners IX, L.P.

its General Partner

 

By:       ARCH Venture Partners IX, LLC

its General Partner

 

By:                       *                      

Keith Crandell

Managing Director

 

 

ARCH VENTURE PARTNERS IX, L.P.

 

By:       ARCH Venture Partners IX, LLC

its General Partner

 

By:                           *                             

Keith Crandell

Managing Director

 

 

ARCH VENTURE PARTNERS IX, LLC

 

By:                            *                               

Keith Crandell

Managing Director

 

 

ARCH VENTURE FUND IX OVERAGE, L.P.

 

By:       ARCH Venture Partners IX Overage, L.P.

its General Partner

 

By:       ARCH Venture Partners IX, LLC

its General Partner

 

By:                       *                      

Keith Crandell

Managing Director

 

 

ARCH VENTURE PARTNERS IX OVERAGE, L.P.

 

By:       ARCH Venture Partners IX, LLC

its General Partner

 

By:                           *                             

Keith Crandell

Managing Director

 

CUSIP No. 92764N 102

13D

Page 15 of 17 Pages

 

 

 

 

 

 

ARCH VENTURE PARTNERS IX, LLC

 

By:                            *                               

Keith Crandell

Managing Director

 

 

                                  *                                 

Keith Crandell

 

 

               0;                   *                                 

Clinton Bybee

 

 

                                  *                                 

Robert Nelsen

 

 

 

 

 

 

 

 

 

* By:   /s/ Mark McDonnell                  

Mark McDonnell

Attorney-in-Fact

 

 

*       This Amendment No. 6 to the Schedule 13D was executed by Mark McDonnell pursuant to a Power of Attorney filed as Exhibit 24 to the Form 3 relating to the beneficial ownership of shares of Vir Biotechnology, Inc. by the Reporting Persons filed with the Securities and Exchange Commission on October 10, 2019 and incorporated herein in its entirety by reference.

 

CUSIP No. 92764N 102

13D

Page 16 of 17 Pages

 

Exhibit 1

AGREEMENT OF JOINT FILING

 

Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, the undersigned hereby agree that only one statement containing the information required by Schedule 13D need be filed with respect to the ownership by each of the undersigned of shares of Common Stock of Vir Biotechnology, Inc.

 

This Agreement may be executed in any number of counterparts, each of which shall be deemed an original.

 

Dated:        September 13, 2022

 

ARCH VENTURE FUND IX, L.P.

 

By:       ARCH Venture Partners IX, L.P.

its General Partner

 

By:       ARCH Venture Partners IX, LLC

its General Partner

 

By:                       *                      

Keith Crandell

Managing Director

 

 

ARCH VENTURE PARTNERS IX, L.P.

 

By:       ARCH Venture Partners IX, LLC

its General Partner

 

By:                           *                             

Keith Crandell

Managing Director

 

 

ARCH VENTURE PARTNERS IX, LLC

 

By:                            *                               

Keith Crandell

Managing Director

 

 

ARCH VENTURE FUND IX OVERAGE, L.P.

 

By:       ARCH Venture Partners IX Overage, L.P.

its General Partner

 

By:       ARCH Venture Partners IX, LLC

its General Partner

 

By:                       *                      

Keith Crandell

Managing Director

 

 

ARCH VENTURE PARTNERS IX OVERAGE, L.P.

 

By:       ARCH Venture Partners IX, LLC

its General Partner

 

By:                           *                             

Keith Crandell

Managing Director

 

CUSIP No. 92764N 102

13D

Page 17 of 17 Pages

 

 

 

 

 

ARCH VENTURE PARTNERS IX, LLC

 

By:                            *                               

Keith Crandell

Managing Director

 

 

                                  *                                 

Keith Crandell

 

 

                                  *                                 

Clinton Bybee

 

 

                                  *                                 

Robert Nelsen

 

 

 

* By:   /s/ Mark McDonnell                  

Mark McDonnell as

Attorney-in-Fact

 

 

 

*          This Agreement of Joint Filing was executed by Mark McDonnell pursuant to a Power of Attorney filed as Exhibit 24 to the Form 3 relating to the beneficial ownership of shares of Vir Biotechnology, Inc. by the Reporting Persons filed with the Securities and Exchange Commission on October 10, 2019 and incorporated herein in its entirety by reference.